These are courtesy translations of local news provided by the U.S. Army Garrison Poland Public Affairs team for the benefit the ...

The company’s product candidates include VERVE-101, which is being evaluated in the Heart-1 trial, an open-label Phase 1b clinical trial, as well as changes in blood PCSK9 protein and LDL-C ...